spheres_v1

GIRx is developing small molecule agents to treat diabetes, obesity and other metabolic conditions.

GIRx focuses on the development of agents that are safer because they act in the GI tract and are not absorbed into the blood stream, thereby avoiding adverse side effects associated with systemic exposure. Our initial GI-restricted agents target receptors that activate hormone-releasing cells in the GI tract to initiate the body’s natural L Cell release of metabolic hormones GLP-1 and PYY to safely treat Type 2 diabetes and obesity.

GIRx is identifying additional receptors in the human GI tract for the development of additional GI-restricted agents that modulate the body’s release of additional metabolic hormones.

_

_